MedDRA preferred term · inflamed skin

Dermatitis: adverse event reports recording this term

20,381 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

20,381
reports recording the term: 0.1% of all reports; 1,939
reports, 12 months to June 2026: 1,796 in the 12 months before; 49%
marked serious by the reporter: 57.4% across all reports; 2.9%
record death among outcomes, as reported: 9.1% across all reports

20,381 reports in FDA's adverse event database record the MedDRA term "Dermatitis" (in plain words, inflamed skin): 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,939 reports recorded it in the 12 months to June 2026, close to the 1,796 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 49% are marked serious, 2.9% include death among the outcomes and 19.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Dupixent, Humira and Methotrexate. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Dupixent	Interleukin-4 receptor alpha antagonist	4,577	1%
Humira	—	657	0.1%
Methotrexate	Folate analog metabolic inhibitor	427	0.2%
Enbrel	Tumor necrosis factor blocker	399	0.1%
Cosentyx	Interleukin-17A antagonist	292	0.2%
Prolia	RANK ligand inhibitor	258	0.2%
Carboplatin	Platinum-based drug	255	0.2%
Remicade	Tumor necrosis factor blocker	226	0.1%
Prednisone	Corticosteroid	219	0.1%
Rituximab	CD20-directed cytolytic antibody	201	0.1%
Docetaxel	Microtubule inhibitor	187	0.3%
Cisplatin	Platinum-based drug	181	0.3%
Dupilumab	Interleukin-4 receptor alpha antagonist	179	1.4%
Nivolumab	Programmed death Receptor-1 blocking antibody	178	0.4%
Fluorouracil	Nucleoside metabolic inhibitor	171	0.3%
Orencia	Selective T cell costimulation modulator	166	0.2%
Actemra	Interleukin-6 receptor antagonist	161	0.2%
Paclitaxel	Microtubule inhibitor	141	0.2%
Sulfasalazine	Aminosalicylate	140	0.3%
Proactiv Solution Daily Protection Plus Sunscreen Spf 30	—	138	1.3%
Infliximab	Tumor necrosis factor blocker	137	0.3%
Pembrolizumab	Programmed death Receptor-1 blocking antibody	136	0.4%
Fosamax	Bisphosphonate	133	0.4%
Capecitabine	Nucleoside metabolic inhibitor	124	0.2%
Keytruda	Programmed death Receptor-1 blocking antibody	123	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Interleukin-4 receptor alpha antagonist	4,756	1%	1.2%
Tumor necrosis factor blocker	1,138	0.1%	0.1%
Kinase inhibitor	912	0.1%	0.1%
Corticosteroid	707	0.1%	0%
Programmed death Receptor-1 blocking antibody	664	0.3%	0.3%
Folate analog metabolic inhibitor	580	0.2%	0.1%
Platinum-based drug	525	0.2%	0.2%
Nucleoside metabolic inhibitor	460	0.1%	0%
Nonsteroidal anti-inflammatory drug	444	0.1%	0%
Microtubule inhibitor	346	0.2%	0.2%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.7%139

2 to 112.7%548

12 to 175.3%1,087

18 to 4419%3,882

45 to 6423.2%4,720

65 to 7411.3%2,294

75 and over7.2%1,470

Age not given30.6%6,241

Patient sex

Female56.8%11,584

Male33.1%6,755

Not given10%2,042

Grey bar: all 20,646,523 reports in the database. 66.7% of these reports give the United States as the country.

Questions about "Dermatitis"

What does "Dermatitis" mean in an adverse event report?

In plain language: inflamed skin. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record dermatitis?

20,381 reports through June 2026 (0.1% of all reports), 1,939 of them in the latest 12 months.

Which drugs appear most often in these reports?

Dupixent (4,577), Humira (657), Methotrexate (427), Enbrel (399) and Cosentyx (292). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.